RxDoctor Payments Data

Jamie Fernandez

Psychiatry · Tampa, FLNPI 1326176736

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $299,953 of the $417,741 with a category attached, or 71.8%. Johnson & Johnson accounts for 90.1% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2022 at $133,642 and has fallen 98.2% since, to $2,418 in 2025. Among psychiatry clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$417,741in general payments, 2019–2025

Across 570 payments — averaging $732.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$377K
  • Axsome Therapeutics, Inc.$12K
  • AbbVie$8K
  • Biogen$5K
  • Neurocrine Biosciences, Inc.$4K
  • Sage Therapeutics, LLC$4K
  • plus $8K from 15 others
$2,809,668in research payments, 2019–2025

Across 303 payments — averaging $9272.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$1.5M
  • Janssen Research & Development, LLC$511K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$358K
  • Novartis$280K
  • Neurocrine Biosciences, Inc.$64K
  • AbbVie$53K
  • plus $81K from 2 others

What the payments were for

  • Consulting fees$53,10913%
  • Speaking & faculty fees$299,95372%
  • Travel & lodging$51,85212%
  • Food & beverage$12,7803%
  • Education$480%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$417,741 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole14$20,233
Aripiprazole26$1,475
Lamotrigine38$607
Mirtazapine35$560
Bupropion XlBupropion Hcl27$522
Trazodone Hcl21$412
Desvenlafaxine Succinate ErDesvenlafaxine Succinate24$334
Fluoxetine Hcl13$184
Alprazolam28$183
Zolpidem Tartrate25$177
Lorazepam11$141
Escitalopram Oxalate11$122
Quetiapine Fumarate16$119
Sertraline Hcl12$102
Propranolol Hcl11$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$355$20,23314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →